Back to top

Analyst Blog

Merrimack Pharmaceuticals, Inc. (MACK) recently reached the patient enrollment target in the NAPOLI-1 study being conducted on its oncology candidate, MM-398.

MM-398 is currently in phase III development for the second-line treatment of pancreatic cancer patients, whose disease has progressed after being treated with Eli Lilly and Company’s (LLY - Analyst Report) Gemzar (gemcitabine).

MM-398 was granted orphan drug designation by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) in 2011, for the treatment of pancreatic cancer. MM-398 is being evaluated in several phase I and phase II studies for other types of cancer as well.

Merrimack has an assignment, sublicense and collaboration agreement with PharmaEngine, Inc. Under the agreement, Merrimack reacquired the rights to MM-398 in Europe and certain other countries. Merrimack made an upfront payment of $10 million to PharmaEngine and will be making milestone payments.

Merrimack also has a license and collaboration agreement with Sanofi (SNY - Analyst Report) for the development of another oncology candidate, MM-121. MM-121 is being evaluated for multiple cancer indications including breast cancer (phase II).

We note that Merrimack has another oncology candidate, MM-111, in its pipeline. Last month, the company advanced MM-111 into phase II development for the treatment of advanced gastric, esophageal and gastroesophageal junction (GEJ) cancers.

Other early-stage pipeline candidates at Merrimack include MM-302, MM-151 and MM-141. MM-302 is being developed for the treatment of breast cancer, while MM-151 and MM-141 are being developed for the treatment of solid tumors.

Merrimack currently carries a Zacks Rank #3 (Hold). At present, companies like Gilead Sciences Inc. (GILD - Analyst Report) look well-positioned with a Zacks Rank #1 (Strong Buy).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%